Erwin G Van Meir
Erwin G Van Meir is an expert in Oncology at University of Alabama at Birmingham (United States). As of October 2026, ScienceLeadR ranks Erwin G Van Meir in the top 1% of experts worldwide for Glioma. Erwin G Van Meir has authored 292 publications, the most recent in 2026. SLR score: 1,318 (community average: 125). How the SLR is computed.
LeadR Profile
Oncology
Subspecialties: Neurology - Genetics
Main Topics
Publications and Clinical Studies
Profile data updated on
Organizations
Career arc: 1990 - 2026
Number : 292
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Therapeutic targeting of adhesion GPCRs: a status update and future potential. PMID 42030458 — tissue adhesions, drug development, drug discovery, drug design, therapeutics, ligands | Expert Opin Drug Discov | 2026 | 0 |
| Exploring the immune environment of glioblastoma in humanized mouse models. PMID 41913047 — brain neoplasms, cells, blood, killer cells, natural, neoplasms, glioblastoma, therapeutics, environment, heterografts | Neuro Oncol | 2026 | 0 |
| Adhesion G protein-coupled receptors. PMID 41895071 — tissue adhesions, gtp-binding proteins, receptors, g-protein-coupled, pharmacology, therapeutics | Pharmacol Rev | 2026 | 0 |
| The Emerging Role of Metabolic Interventions in Uveal Melanoma. PMID 41110618 — cells, melanoma, neoplasms, neoplasm metastasis, therapeutics, environment, prognosis, uveal melanoma | Semin Cancer Biol | 2025 | 0 |
| Tumor-initiating genetics and therapy drive divergent molecular evolution in IDH-mutant gliomas. PMID 40791422 — radiotherapy, genes, glioma, genetics, astrocytoma, neoplasms, genome, therapeutics, oligodendroglioma, mutation, evolution, molecular | bioRxiv | 2025 | 0 |
LeadR Networks
Main global connection map